The potential of NT-0796 to improve the efficacy and tolerability of existing GLP-1RA obesity therapies will be further investigated in NodThera’s upcoming Phase 2 combination trial, RESOLVE-2 ...

In a world of algorithms and buzzwords, we’re cutting through the noise. Applied, Not Artificial explores how AI delivers real impact in pharmaceutical commercialization — when it’s grounded in ...

I am delighted that, following our recently closed $50 million Series D financing, we have accelerated our ... an intracellular sensor and master switch that modulates inflammation, plays a key role ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

Chicken is going to be harder to come by in markets from China to Europe after a case of bird flu was detected in top exporter Brazil. Summer is just around the corner in the Northern Hemisphere ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Tesla Inc. investors are in a good mood Thursday, as they look for a now full-time Elon Musk as chief executive to clear the path for the electric-vehicle giant’s stock to target a return to rec ...

The VGChartz sales comparison series of articles are updated monthly and each one focuses on a different sales comparison using our estimated video game hardware figures. The charts include ...

From seed to Series C and beyond—founders and VCs of all stages are heading to Boston. Be part of the conversation. Save $200+ now and tap into powerful takeaways, peer insights, and game ...

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming ...

Five Key Charts to Watch in Global Commodities This Week. Clarice Couto, Brian K. Sullivan and Will Wade . Mon, May 26, 2025, 11:13 AM 3 min read ...